JP Morgan Week 2025 – Tony Lee and Ed Ahn

One of the key open questions in cell and gene therapy is which will win out: autologous cell therapies, where the patient’s own blood is modified at the bedside, or allogeneic therapies, created with donor cells and available “off the shelf”.

So far, most successful, approved cell therapies have been autologous. But at JP Morgan 2025 editor-in-chief Jonah Comstock spoke with the co-CEOs of Medipost, a company that’s successfully created an allogeneic cell therapy product in Korea for the treatment of osteoarthritis – the first allogeneic cell therapy to secure regulatory approval anywhere in the world.

In the video below, Jonah chats with Medipost’s Tony Lee and Ed Ahn about their cell therapy and how they’re moving to bring it to other countries, including the United States, where they plan to start their phase 3 trial at the end of this year.

They discuss supply chain challenges, the importance of real-world evidence, and broader trends in the world of cell and gene therapies. Check out the full video below to learn more about a groundbreaking company that’s pursuing rapid global expansion.